U.S. Machinery Stock News

In February 2026, Vaxcyte, Inc. reported a full-year 2025 net loss of US$766.63 million and completed a US$408.1 million follow-on equity offering, while also filing an additional US$500 million at-the-market program and a US$473.86 million shelf registration related to employee stock plans. These moves collectively highlight Vaxcyte’s reliance on equity financing to support its vaccine pipeline while absorbing widening losses, a pattern that can influence how investors assess funding risk...

In February 2026, Agilent Technologies reported first-quarter 2026 sales of US$1,798 million, with net income of US$305 million, and raised full-year 2026 revenue guidance to a range of US$7.30 billion to US$7.50 billion while issuing new second-quarter revenue guidance of US$1,790 million to US$1,820 million. Management’s decision to increase full-year revenue guidance while first-quarter earnings per share were slightly lower than a year earlier highlights confidence in cost control and...

Crown Castle (CCI) has been back in focus after fourth quarter 2025 results topped analyst estimates, followed by 2026 guidance and plans to sell its small cell and fiber businesses later this year. See our latest analysis for Crown Castle. The recent earnings beat, new 2026 guidance and the plan to sell the small cell and fiber businesses have coincided with an 11.81% 1-month share price return from Crown Castle, even though the 1-year total shareholder return of a 2.70% decline and 5-year...

Primerica stock reaction and recent performance snapshot Primerica (PRI) shares recently closed at US$257.31. The stock has seen mixed returns, with a 2.6% decline over the past day, a 6.7% decline over the past month, and a modest gain over the past 3 months. See our latest analysis for Primerica. While the 1-day share price return of 2.6% and 30-day share price return of 6.7% declines point to fading short term momentum, the 3-year total shareholder return of 59.38% and 5-year total...

In recent days, AGCO Corporation appointed former Corteva Agriscience CEO James C. Collins, Jr. to its Board of Directors, while also updating its annual incentive plan and highlighting significant expected 2026 tariff costs of about US$105 million to US$110 million at a major investor conference. This combination of governance changes, technology-focused initiatives, and tariff-related headwinds gives investors fresh information on how AGCO is balancing growth ambitions with cost and risk...

Humana (HUM) is in focus after pricing a US$1 billion junior subordinated notes offering due 2056. The notes received a stable credit rating from AM Best, drawing attention to the stock’s capital structure. See our latest analysis for Humana. Despite fresh headlines around the junior subordinated notes and new value based cardiac care partnerships, Humana’s 30 day share price return of 7.63% and year to date share price return of 32.26% highlight ongoing pressure. This is also reflected in a...

Earlier this month, Crossmint announced it is partnering with Western Union to support the rollout of USDPT, a U.S. dollar-denominated stablecoin issued on Solana, and to integrate with Western Union’s new Digital Asset Network that connects digital dollars to cash access at more than 360,000 collection points worldwide. This move is distinctive because it links on-chain stablecoin transfers directly to Western Union’s global cash payout infrastructure, potentially making digital dollars far...

In March 2026, Takeda and Protagonist Therapeutics announced that the FDA had accepted and granted Priority Review to their New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for adults with polycythemia vera, with a PDUFA target action date in the third quarter of this year. This filing, backed by Phase 3 VERIFY and long-term Phase 2 REVIVE and THRIVE data and multiple expedited regulatory designations, positions rusfertide as a potential new option for improving...

In early March 2026, Mobix Labs, Inc. reported new production purchase orders for its high-reliability electromagnetic interference protection components used in Gulfstream business jets and the U.S. Navy’s Tomahawk cruise missile program, alongside a change to its bylaws reducing the shareholder meeting quorum requirement to one-third of voting power. The fresh aerospace and defense orders underline Mobix Labs’ role as an already-qualified supplier embedded in mission-critical platforms...

Before we get into the numbers, if you are wondering whether Booking Holdings is priced attractively today, this article will walk through what the current market price might be implying about its value. Over the very short term the stock has been mixed, with a 7.3% return over the last 7 days and 2.1% over the last 30 days, while year to date the share price shows a 14.5% decline and a 1.9% decline over the last year. This is set against longer term returns of 86.9% over 3 years and 93.1%...

What Mercury General’s Recent Performance Tells You Mercury General (MCY) has attracted fresh attention after a strong 1 year total return of 71.35%, alongside mixed shorter term moves, including a month decline of about 4.95% and a modest gain over the past 3 months. See our latest analysis for Mercury General. The recent pullback, including a 1 month share price return of about a 5% decline from a last close of US$90.48, sits against a much stronger 1 year total shareholder return of...

NIQ Global Intelligence: Recent Price Moves and Business Snapshot NIQ Global Intelligence (NIQ) has drawn fresh attention after recent share price swings, with the stock down 2.5% over the past day, weaker over the past week, but positive over the past month. For investors looking at the consumer data and analytics space, NIQ sits in an interesting position. The company reports annual revenue of US$4,198.4m and a net loss of US$353.3m, while its value score stands at 6. Over the past 3...

RXO (RXO) stock has been under pressure after reports of rising transportation costs and large share reductions by some institutional holders, which have sharpened investor focus on margin resilience and balance sheet strength. See our latest analysis for RXO. RXO’s recent selloff, including a 1 day share price return of 11.07% decline and a 7 day share price return of 13.91% decline to US$13.74, comes after months of softer results. The 1 year total shareholder return of 30.64% decline shows...

The weak February U.S. jobs report, which showed a loss of 92,000 jobs and unemployment at 4.4%, triggered a 3.6% drop in Enova International (ENVA), highlighting investor concern around credit conditions and demand. See our latest analysis for Enova International. That jobs-driven drop comes after a tougher few weeks for the share price, with a 30 day share price return of a 14.6% decline and a year to date share price return of a 15.05% decline, even though the 1 year total shareholder...

Cabot (CBT) is back in focus after first quarter fiscal 2026 results that beat earnings estimates, but came with lower year over year sales and a trimmed adjusted EPS outlook. See our latest analysis for Cabot. The earnings beat has not stopped selling pressure in the short term, with a 1 day share price return of 5.40% decline and a 7 day share price return of 8.04% decline. At the same time, the 90 day share price return of 8.49% and 5 year total shareholder return of 46.88% point to a...

Septerna, Inc. recently reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing favorable tolerability, once-daily pharmacokinetics and clinical proof-of-mechanism in humans. The company’s decision to move SEP-631 into a Phase 2b trial for chronic spontaneous urticaria, alongside an open-label study in chronic inducible urticaria, highlights a focused push into difficult-to-treat allergic skin conditions. We will now examine how SEP-631’s...

Wingstop stock snapshot after recent performance Wingstop (WING) has been on many watchlists after a recent stretch of weaker returns, including a 3% decline in the latest session and double digit pullbacks over the past month and past 3 months. See our latest analysis for Wingstop. That 3% one day share price drop at around $229.17 caps a weaker run, with 7 day and 30 day share price returns of 11.69% and 13.20% declines, while the 5 year total shareholder return of 88.85% shows a very...

Boston Scientific (BSX) is under pressure after a series of securities class actions and investigations tied to its U.S. electrophysiology segment, where underperformance, reduced guidance and alleged misstatements have raised fresh questions for shareholders. See our latest analysis for Boston Scientific. At a share price of US$71.35, Boston Scientific has seen pressure build, with a 1 day share price return of 2.25% decline and a 90 day share price return of 23.97% decline, while the 3 year...

Why Stock Yards Bancorp is on investors’ radar today Stock Yards Bancorp (SYBT) has drawn fresh attention after recent share price moves, with the stock showing a month return near 9% decline and a past 3 months return near 4% decline. For investors tracking regional banks, those short term moves sit alongside a 1 year total return near 5% decline and longer term 3 year and 5 year total returns around 29%, supported by reported revenue of US$390.56m and net income of US$140.15m. See our...

Radian Group (RDN) has put an omnibus shelf registration in place covering common and preferred shares, debt securities, warrants, rights, stock purchase contracts, and units, providing the insurer with flexible access to future funding. See our latest analysis for Radian Group. Recent moves by Radian Group, including the Inigo acquisition and divestment of non core businesses, come as the shares trade at US$33.90 with a 1 year total shareholder return of 8.89% and a 3 year total shareholder...

Celldex Therapeutics (CLDX) has caught investor attention after presenting fresh Phase 2 and open label extension data for barzolvolimab in multiple urticaria indications at the AAAAI 2026 meeting in Philadelphia. See our latest analysis for Celldex Therapeutics. The latest barzolvolimab readouts arrive after a busy few weeks for Celldex, including multiple AAAAI presentations, completion of enrollment in the global Phase 3 CSU program and full year 2025 results that showed revenue of US$1.55...

If you are wondering whether Levi Strauss at around US$19.60 is a bargain or fully priced, you are not alone. The stock has been attracting attention from investors who care about what they are really paying for each dollar of fundamentals. The share price has seen a 11.6% decline over the last 7 days and is down 4.6% over 30 days and 5.9% year to date, yet it still shows a 22.3% return over 1 year and 33.0% over 3 years, with a 11.5% decline across 5 years. Recent headlines around Levi...

Plains All American Pipeline (PAA) recently raised its annualized distribution 10% to $1.67 per unit. The increase is tied to its fee-based, volume driven cash flows and coincides with rising oil prices amid heightened U.S. Iran tensions. See our latest analysis for Plains All American Pipeline. The distribution move comes as the unit price has been strong, with a 30 day share price return of 13.81% and a year to date share price return of 21.25%. The 5 year total shareholder return of...

Earlier this week, SM Energy Company completed pricing of an upsized US$1.00 billion private offering of 6.625% senior notes due 2034, issued at par, with proceeds earmarked mainly to fund a cash tender offer for up to US$750 million of higher‑coupon 8.375% notes maturing in 2028. This refinancing, coming soon after the Civitas merger, reshapes SM Energy’s debt profile by lowering coupon costs and pushing a portion of its maturities out to 2034 while targeting the acquired 2028 notes. Next,...